Home » Stocks » USRM

U.S. Stem Cell, Inc. (USRM)

Stock Price: $0.0371 USD 0.0001 (0.27%)
Updated May 7, 2021 3:59 PM EDT - Market closed
Market Cap 15.10M
Revenue (ttm) 4.43M
Net Income (ttm) -3.60M
Shares Out 396.64M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.0371
Previous Close $0.0370
Change ($) 0.0001
Change (%) 0.27%
Day's Open 0.0325
Day's Range 0.0325 - 0.0374
Day's Volume 816,157
52-Week Range 0.0033 - 0.0870

News

There are no news available yet.

About USRM

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a p... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2008
CEO
Mike Tomas
Employees
10
Stock Exchange
OTCMKTS
Ticker Symbol
USRM
Full Company Profile

Financial Performance

In 2018, U.S. Stem Cell's revenue was $6.70 million, an increase of 21.38% compared to the previous year's $5.52 million. Losses were -$2.16 million, -37.95% less than in 2017.

Financial Statements